Shanghai Henlius Biotech Gets Australian Approval for Phase 3 Trials for Postmenopausal Osteoporosis Injectable
Shanghai Henlius Biotech Gets Australian Approval for Phase 3 Trials for Postmenopausal Osteoporosis Injectable
上海亨利烏斯生物科技公司獲得澳大利亞批准進行絕經後骨質疏鬆症注射劑3期試驗
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊